Korea Exchange’s decision on Kyungnam Pharm to make subject to Substantive Examination for Listing Eligibility

The Exchange Korea reviewed possibilities to delist Kyungnam Pharm based on general qualifications in accordance with Article 38 of 2 Item of Number 2 of the KOSDAQ Rules, and officially announced that the company is subject to the Substantive Examination for Listing Eligibility on the 22^nd.

Under the decision, the Exchange Korea will inform Kyungnam Pharm of the examination schedule and proce...